Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.43 USD | +6.21% | -14.48% | +9.47% |
06-18 | Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Ahead of Speeches by Fed Officials | MT |
06-14 | Oppenheimer Adjusts UroGen Pharma Price Target to $40 From $32, Maintains Outperform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.47% | 559M | |
+14.80% | 122B | |
+19.95% | 113B | |
+8.24% | 22.84B | |
-19.85% | 20.72B | |
-16.19% | 16.51B | |
-13.50% | 16.39B | |
-44.35% | 15.83B | |
+1.93% | 13.49B | |
+66.72% | 11.67B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Transcript : UroGen Pharma Ltd., Q4 2023 Earnings Call, Mar 14, 2024